Donald Hooker
Stock Analyst at Keybanc
(2.53)
# 2,262
Out of 4,735 analysts
82
Total ratings
55.95%
Success rate
9.22%
Average return
Main Sectors:
Stocks Rated by Donald Hooker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Overweight | $180 → $100 | $9.50 | +952.63% | 18 | Feb 23, 2022 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $450 → $390 | $169.81 | +129.67% | 5 | Feb 17, 2022 | |
| DGX Quest Diagnostics | Maintains: Overweight | $168 → $170 | $152.65 | +11.37% | 4 | Dec 13, 2021 | |
| IQV IQVIA Holdings | Maintains: Overweight | $270 → $290 | $205.69 | +40.99% | 4 | Nov 17, 2021 | |
| PHR Phreesia | Maintains: Overweight | $70 → $73 | $27.35 | +166.91% | 8 | Jul 12, 2021 | |
| RXRX Recursion Pharmaceuticals | Initiates: Overweight | $36 | $6.88 | +423.26% | 1 | May 11, 2021 | |
| AMWL American Well | Initiates: Sector Weight | n/a | $10.98 | - | 1 | Apr 16, 2021 | |
| VEEV Veeva Systems | Maintains: Overweight | $332 → $353 | $223.04 | +58.27% | 2 | Feb 17, 2021 | |
| HQY HealthEquity | Downgrades: Sector Weight | n/a | $104.74 | - | 11 | Dec 2, 2020 | |
| MMS Maximus | Maintains: Overweight | $80 → $84 | $79.68 | +5.42% | 2 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $10.17 | - | 8 | Jul 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $170 | $243.99 | -30.33% | 7 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $205.07 | - | 6 | Sep 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $68 → $46 | $1.73 | +2,566.36% | 2 | Nov 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $22.09 | - | 1 | Oct 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $347.52 | - | 2 | Jul 10, 2017 |
Teladoc Health
Feb 23, 2022
Maintains: Overweight
Price Target: $180 → $100
Current: $9.50
Upside: +952.63%
Charles River Laboratories International
Feb 17, 2022
Maintains: Overweight
Price Target: $450 → $390
Current: $169.81
Upside: +129.67%
Quest Diagnostics
Dec 13, 2021
Maintains: Overweight
Price Target: $168 → $170
Current: $152.65
Upside: +11.37%
IQVIA Holdings
Nov 17, 2021
Maintains: Overweight
Price Target: $270 → $290
Current: $205.69
Upside: +40.99%
Phreesia
Jul 12, 2021
Maintains: Overweight
Price Target: $70 → $73
Current: $27.35
Upside: +166.91%
Recursion Pharmaceuticals
May 11, 2021
Initiates: Overweight
Price Target: $36
Current: $6.88
Upside: +423.26%
American Well
Apr 16, 2021
Initiates: Sector Weight
Price Target: n/a
Current: $10.98
Upside: -
Veeva Systems
Feb 17, 2021
Maintains: Overweight
Price Target: $332 → $353
Current: $223.04
Upside: +58.27%
HealthEquity
Dec 2, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $104.74
Upside: -
Maximus
Aug 7, 2020
Maintains: Overweight
Price Target: $80 → $84
Current: $79.68
Upside: +5.42%
Jul 6, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $10.17
Upside: -
Mar 30, 2020
Maintains: Overweight
Price Target: $212 → $170
Current: $243.99
Upside: -30.33%
Sep 23, 2019
Downgrades: Sector Weight
Price Target: n/a
Current: $205.07
Upside: -
Nov 13, 2017
Maintains: Overweight
Price Target: $68 → $46
Current: $1.73
Upside: +2,566.36%
Oct 24, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $22.09
Upside: -
Jul 10, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $347.52
Upside: -